> News
News 2016-12-11T21:08:15+00:00


Viglya wishes to establish transparent and open communication with its stakeholders. This section offers new and updated information regarding the company and the life science sector.

Infarmed: Metamizol e risco de agranulocitose

Na sequência de diversas notícias relativas à utilização de medicamentos contendo metamizol, o Infarmed informa: O metamizol é um medicamento utilizado para o tratamento da dor e febre há cerca de 40 anos. Em Portugal, [...]


FDA warns StemGenex Biologic Laboratories LLC of illegally marketing an unapproved cellular product manufactured in a facility with significant manufacturing violations, putting patients at risk

The U.S. Food and Drug Administration has warned StemGenex Biologic Laboratories LLC (StemGenex) of San Diego, Calif; its owner/manager Rita F. Alexander and laboratory and medical director Jenny R. Galloway, M.D. about marketing a purported stem cell [...]


EMA: Human medicines highlights – November 2018

This newsletter is addressed primarily to organisations representing patients, consumers and healthcare professionals. It provides a summary of key information relating to medicines for human use published during the previous month by the European Medicines [...]

Find out why Viglya is your strategic partner in drug development.Read more